| abstract |
Compounds of formula (I) are disclosed wherein R and R are substituents on rings A and are independently —SONR, —C (O) NR, —NRSOR, —NRC (O) R, —SOOR, —C (O) OR, -OSOR or —OC (O) R, R and R are independently hydrogen or lower alkyl or R and R together are - (CH) -, - (CH) - or - (CH) -, or R, or R may being an electron pair, R and R are independently hydrogen, alkyl, substituted alkyl, cyano, halogen, nitro, -SR, -C (O) R, -SOOR, -OSOR, -SONR, -NRSOR, -OC (O) R, —C (O) OR, —C (O) NR, —NRC (O) R, —OR or —NR, R and R, each independently of one another, are hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aryl ( ness.) alkyl, substituted aryl (ness.) alkyl, heteroaryl (ness.) alkyl, substituted heteroaryl (ness.) alkyl, heterocyclyl, substituted heterocyclyl, heteroaryl or substituted heteroaryl, each Y independently of one another means a non-interfering substituent which is not linked to the naphthalene ring via an azo or amide bond, each x independently represents 0, 1 or 2, and the linker combines the carbon labeled “c” with the carbon labeled “d” or their pharmaceutically acceptable salts, in the form one stereoisomer or a mixture of stereoisomers, etc. known for the treatment of conditions associated with hyperglycemia, especially for the treatment of type II diabetes dinaphthylureas. These compounds are useful for stimulating the kinase activity of an insulin receptor, activating an insulin receptor and stimulating glucose uptake. Also disclosed are pharmaceutical compositions comprising compounds with antidiabetic activity. |